Institutional members access full text with Ovid®

Share this article on:

Salvage Therapy for Hodgkin’s Lymphoma

Quddus, Fahd MD; Armitage, James O. MD

doi: 10.1097/PPO.0b013e3181a1438a
Special Issue on Hodgkin's Lymphoma: Original Article

Hodgkin’s lymphoma (HL) is a clonal lymphoid malignancy that affects over 7000 patients in the United States annually. The disease remains one of the great success stories in the recent history of cancer treatment. More than 80% of HL patients will be expected to be long-term survivors because of recent advances in radiation therapy and combined chemotherapy. However, for the subset of patients who relapse after initial therapy, HL remains a challenging disease. Indeed, for patients who relapse after salvage high-dose chemotherapy and autologous stem cell transplant, effective therapeutic options remain limited, and further new therapies are warranted. This article provides a review of the current literature regarding salvage therapy for HL.

From the Section of Hematology and Oncology, UNMC Oncology/Hematology Section, 987680 Nebraska Medical Center, University of Nebraska, Omaha, NE.

Reprints: Fahd Quddus, MBBS, Section of Hematology and Oncology, UNMC Oncology/Hematology Section, 987680 Nebraska Medical Center, University of Nebraska, Omaha, NE 681980-7680. E-mail: fquddus@unmc.edu.

© 2009 Lippincott Williams & Wilkins, Inc.